| Name | Title | Contact Details |
|---|
Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.
Changing the paradigm in spinal diagnosis.
Napp Technologies is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
We want to produce and market early-warning systems for specific smells related to diseases, safety and well-being. We want to enhance the time and cost efficiency in diagnosing diseases through breath analysis and Microbe detection.